ArticleBMC endocrine disorders2025
Establishment of age-related AMH screening cutoffs in Chinese women with PCOS: a retrospective study using propensity score matching analysis.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age- and BMI-stratified assessment of serum anti-Müllerian hormone as a biomarker for polycystic ovary syndrome diagnosis in Chinese women.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5-18% of women worldwide. This disorder is characterized by two core pathological features: ovulatory dysfunction and hyperandrogenism.
methodA retrospective analysis was conducted on cases treated at Hangzhou Women's Hospital from July 2021 to November 2023. Based on age, we conducted propensity score matching analysis in a 1:1 ratio and statistical analysis using SPSS software, plotted receiver operating characteristic curves, and obtained the area under the curve, the optimal anti-Müllerian hormone screening threshold, corresponding sensitivity, specificity, Youden index, correct diagnostic rate, positive predictive value, negative predictive value. Age-related anti-Müllerian hormone screening criteria with polycystic ovary syndrome were established and evaluated based on the optimal anti-Müllerian hormone screening cutoff for each group. The above results were validated by the validation group. And Kappa consistency test was conducted between the age-related anti-Müllerian hormone screening test and 2003 Rotterdam criteria for polycystic ovary syndrome.
resultsThe screening criteria for age-related anti-Müllerian hormone with polycystic ovary syndrome were: ≥7.46 ng/ml (20-24-year-old), ≥ 4.55 ng/ml (25-29-year-old), ≥ 4.19 ng/ml (30-34-year-old), ≥ 3.57 ng/ml (35-39-year-old).
conclusionOur research indicates that age specific AMH threshold values show promising sensitivity and specificity for PCOS screening in the validation cohort. These findings indicate the potential utility of AMH based screening, but emphasize the need for optimization and validation in larger multicenter studies before clinical implementation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.